Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy

Psychiatria Danubina

Volumn 22, Issue 2, 2010, Pages 335-337

  Mihaljević Peleš, Alma ^a,b   Šagud, Marina ^a   Božina, Nada ^b   Živković, Maja ^c   Jovanović, Nikolina ^a  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c Neuropsihijatrijska bolnica   (Croatia)

Author keywords

Antipsychotics; Isoenzymes P450; Pharmacogenetics; Polymorphisms

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CODEINE; DIAZEPAM; DULOXETINE; FLUINDOSTATIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; SERTRALINE; UNINDEXED DRUG; VALPROIC ACID; ZUCLOPENTHIXOL;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOLOGY; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT;

ALLELES; ANTIPSYCHOTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; HUMANS; INDIVIDUALIZED MEDICINE; ISOENZYMES; METABOLIC CLEARANCE RATE; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 77954360760     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Arranz MJ & de Leone J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research Molecular Psychiatry 2007; 12: 707-747.
2. Arranz MJ, Dawson E, Shaikh S, Sham P, Sharma T, Aitchison K et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995; 39: 417-420.
3. Bertilsson L, Dahl ML, Dalen P & Al-Shurbaji A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-122. (Pubitemid 34264265)
4. Bondy B and Spellmann I.: Pharamaeogenetics of antipsychotics: Useful for the Clinician? Curr Opin Psychiatry. 2007; 20(1);126-130.
5. Brouwers EE, Söhne M, Kuipers S, van Gorp EC, Schellens JH, Koks CH, Beijnen JH & Huitema AD: Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009;29:59-63.
6. De Leon J, Armstrong SC & Cozza KL: Med drug-drug interactions update. The dosing of atypical antipsychotics. Psychosomatics 2005;46: 262-273.
7. de Leon J, Susce MT, Pan RM, Fairchild M, Koch WH & Wedlund PJ: The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27.
8. Eiermann B, Engel G, Johansson I, Zanger UM & Bertilsson L: Theinvolvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997; 44: 439-446.
9. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia Res 1998; 32: 101-6.
10. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473.
11. Kootstra-Ros JE, Smallegoor W & van der WJ: The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 2005; 42: 216-219.
12. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57(Suppl 9): 5-9.
13. Maier W & Zobel A. Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur Arch Psychiatry Clin Neurosci 2008; 258[Suppl 1]:12-20.
14. Mihaljevic-Peles A, Šagud M Božina N, Ž ivković M. Pharmacogenetics and antidepressant treatment in integrative psychiatry perspective. Psychiatria Danubina, 2008; Vol. 20, No. 3, pp 355-355.
15. Miyamoto S, Duncan GE, Marx CE & Lieberman JA: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005; 10:79-104.
16. Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004; 308: 300-306.
17. Nebert DW, Dieter MZ. The evolution of drug metabolism. Pharmacology 2000; 61: 124-135.
18. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276:658-666.
19. Zanger UM, Turpeinen M, Klein K & Schwab M: Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093-1198.